Nakajima T, Takashima Y, Furuya A, Ozawa Y, Kawashima Y
Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Chem Pharm Bull (Tokyo). 1990 Apr;38(4):1027-31. doi: 10.1248/cpb.38.1027.
We prepared indomethacin (IM) sustained-release suppositories using sugar ester (SE) as an additive. The suppositories were prepared by the fusion method with IM, SE, and Witepsol H-15 (H-15) and their availabilities in vitro and in vivo were evaluated mainly by the drug release test and the absorption test in rabbits, respectively. The softening point of the suppositories increased with increasing SE content. In the release test with the Muranishi method, slow-release profiles were obtained when the SE content was more than 52.5%. The absorption of IM from these suppositories, however, was very little. In the other release test, e.g. immersion method with gauze, all of the suppositories with SE showed slow-release profiles, and the drug release rates clearly depended on the SE content. The drug was released from the suppositories by the following leaching-type mechanism proposed by Higuchi. The suppository with a 30% SE content showed a sustained-plasma level of IM, but the other suppositories did not. It was concluded that an appropriate content of SE (i.e. 30%) in the suppository base was required to obtain sustained-release because it reasonably regulated the infiltration of rectal fluid into the suppository and the mechanical strength of the suppository against disintegration.
我们使用糖酯(SE)作为添加剂制备了吲哚美辛(IM)缓释栓剂。通过将IM、SE和Witepsol H - 15(H - 15)熔融的方法制备栓剂,其体外和体内可用性分别主要通过药物释放试验和家兔吸收试验进行评估。栓剂的软化点随SE含量增加而升高。在采用村西法的释放试验中,当SE含量超过52.5%时可获得缓释曲线。然而,这些栓剂中IM的吸收很少。在其他释放试验中,如用纱布浸泡法,所有含SE的栓剂均显示出缓释曲线,且药物释放速率明显取决于SE含量。药物通过Higuchi提出的以下溶蚀型机制从栓剂中释放。含30%SE的栓剂显示出IM的持续血浆水平,但其他栓剂则没有。得出结论,栓剂基质中需要适当含量的SE(即30%)以获得缓释效果,因为它合理地调节了直肠液渗入栓剂的程度以及栓剂抗崩解的机械强度。